US biotech firm Dendreon (Nasdaq: DNDN) says it has reached an agreement with Canada’s Valeant Pharmaceuticals International (TSX:VRX) whereby, subject to bankruptcy court approval, Valeant will serve as the “stalking horse” bidder in conjunction with a court-supervised sales process (The Pharma Letter January 28).
Under the terms of the agreement, Valeant would acquire the world-wide rights of prostate cancer therapy Provenge (sipuleucel-T) and certain other Dendreon assets for $296 million, subject to higher and better bids.
“We are pleased to reach this agreement with Valeant and to move forward with the court-supervised sales process,” said Thomas Amick, president and chief executive of Dendreon, adding: “We are confident that this process will result in a strong new owner for Provenge, and that patients will continue to receive treatments with no disruption moving forward.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze